Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Etrade shows after hours trade down to .02? Some kind of error??
well i kept half of my shares looking to re enter and reload at a bit lower pps
good luck hope u get filled
hoping to gap upo to at least .24 in the am
very thin at .24 expect further surging once the cannons start firing again after lunch
awesome thanks for clearing that up bruce that is great
great to see
we all must also consider heavy international investments also as people piece the trail together
imposter smart dna
so is this smartdna apdns smart dna?
I HAVNT SOLD A SINGLE SHARE SINCE .135!!!!!!!
over 9 MILLION VOLUMEEEEEEE
morning all.. So we still have huge volume huge movement and little to put together to figure out why
i have the buy orders set at .04 to load the boat
i dont believe it will go much lower than .04
jmho
what do u all think?
is this run coming to a halt until a pr??
or just consolidation?
I think there are a bit more results than. Many may think!
I will be a buyer at .04 that is the only real support if any
Be realistic never get married to anyy stock . average down at .04 or just get out now
I believe it was an orchestrated takedown with an agenda on bringing it back up with a bang bigger than ever
Time will tell
IMHO
LOOKS LIKE THINGS WILL BEGIN TO HEAT UP
Photo Release -- CytoSorbents Provides Update on ISICEM 2013 Critical Care Conference
Font size: A | A | A
8:00 AM ET 3/26/13 | GlobeNewswire
CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, provides an update on its recent exhibition at the 33 International Symposium on Intensive Care and Emergency Medicine (ISICEM)in Brussels, Belgium last week. This year, approximately 6,000 participants from all over the world attended for an up-to-date review of the most recent, clinically relevant, developments in research, therapy, and management of the critically ill.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=17789
At its newly re-designed booth (see picture inset), CytoSorbents featured its flagship product, CytoSorb(R), the only specifically approved cytokine blood filter in the European Union. The goal of CytoSorb(R) is to prevent or treat organ failure - the cause of nearly half of all deaths in the ICU - by controlling "cytokine storm" and reducing deadly inflammation. CytoSorb(R) has now been used in many different critical care applications, and is generating revenue through direct sales in primarily Germany and Austria, where reimbursement exists. It is also approved for sale throughout all 27 European Union countries, and can be sold, with proper registration, in many other countries outside the E.U.
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, stated, "This ISICEM symposium was one of our most productive conferences we have had to date and we were pleased with the new and ongoing interest in CytoSorb(R). Our mindshare amongst clinicians has clearly increased since last year's conference and our booth traffic was very steady, with potential new customers and existing key opinion leaders who are collaborating with us on additional clinical studies. During our time in Brussels, we advanced our discussions with distributors from many major countries as well as potential strategic corporate partners. This is consistent with our strategy to aggressively expand commercialization of CytoSorb(R) in order to drive future significant revenue growth through both direct and partner sales."
Dr. Chan continued, "At the meeting, our collaborator Dr. John Kellum from University of Pittsburgh Medical Center, spoke to an audience of more than 300 people on 'Reversing sepsis-induced immune suppression' based on findings from his recently published article in the scientific journal, Molecular Medicine,* using our CytoSorb(R) technology. Dr. Kellum highlighted how a reduction of "cytokine storm" using CytoSorb(R) in rat models of sepsis can allow the immune system to target the true area of infection more efficiently, while reducing unintentional injury by immune cells to otherwise healthy vital organs like the lungs, liver and kidneys. We believe this is one of the key mechanisms of action by which CytoSorb(R) may prevent or treat organ failure in humans."
"Additionally, Dr. Dirk Schädler, from the Kiel University presented his poster, entitled, "A multicenter randomized controlled study of an extracorporeal cytokine hemoadsorption device in septic patients." This poster can be found on our investor website at: http://www.cytosorbents.com/invest.htm. Interestingly, an entire session was also devoted to the deadly risks of blood transfusion in critically-ill patients, highlighting the value of our HemoDefend blood purification technology that aims to reduce adverse events related to administering blood."
Dr. Chan concluded, "If one looks at the range of research topics covered at ISICEM, one thing is very clear. CytoSorb(R) is targeting some of the most important unmet medical needs in the ICU. The continued lack of effective therapies for critically-ill patients is remarkable, particularly in the area of controlling inflammation and treating organ failure, making the opportunity for CytoSorb(R) that much more compelling. If it works as intended, CytoSorb(R) has the real potential to revolutionize critical care therapy."
*Namas, RA, et al., "Hemoadsorption reprograms inflammation in experimental gram-negative septic peritonitis: Insights from in vivo and in silico studies" Molecular Medicine, 2012, vol. 18, p. 1366-1374.
About CytoSorbents
CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption. CytoSorb(R), the Company's flagship product, is approved in the European Union as a safe and effective cytokine filter, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the mortality is extremely high, yet no effective treatments exist. Additional information is available on the Company's website: http://www.cytosorbents.com.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and additional CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate and timely financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Form 10-K filed with the SEC on March 30, 2012, which is available at http://www.sec.gov.
View data
CONTACT: Company Contact: CytoSorbents Corporation Dr. Phillip Chan Chief Executive Officer (732) 329-8885 ext. *823 pchan@cytosorbents.com Investor Contact: Alliance Advisors, LLC Alan Sheinwald (914) 669-0222 asheinwald@allianceadvisors.net Valter Pinto (914) 669-0222 x201 valter@allianceadvisors.net
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwMjYzNTEjMjUzNTk=
Wow i am working nights all this week i woke up at 5 after the market closed BOOM WHAT A DAY.
GOd only knows how the pps will react to a serous pr
very exciting
lets just hope that this gem company is finally hitting that point of explosion
we all know that the pps will follow suit
I believe that all of the "insiders" have accumulated as much as they planned and have set this baby off to the next dimension
this is my opinion but we will see how the rest of this week plays out
GLTA !!!!
72000 on the ask at .20
I've forgotten another thing: Dr. Chan said that nobody has to be afraid for competitors. The Cytosorb filter is the only with such a massive capacity (a surface area of more than 5 footballfields) to bind the cytokines. In combination with flow rates of 200 to 400 ml/minute (12 to 24 liter/hour), it has a big superiority (+ very safe + easy to use = much easier to use than hemodialysis or hemofiltration).
Last remark: i have to change my opinion of Dr. Chan. The last 10 weeks, i was angry because of the sinking PPS, his silence + his last speech on moneytv. But in the long term, he has a very good, intelligent businessplan. He works very methodicaly: first building a strong foundation for CTSO with many strong patents, certified productionfacility, EU-approval, DARPA + SBIR-grants, then starting a salesteam under supervision of Dr. STEINER in Germany (the richest EU-country with a big reimbursing). Then meetings with kol's + icu's. There are now testimonials of dying people in the ICU who are now fully recovered thanks to the Cytosorb-filter. German physians are so enthusiastic that they're starting their own investor conducted trials with our filters. It cost nothing to CTSO + these trials are potential goldmines. What can he do more? Awakening Lazarus after 4 days of death with our filter??? Every sensible man knows this is only an investment for the longs. Why selling and putting the money on the bank with no return at all???? I'm in for long and for now, i'm happy + reassured. Our reward will be bigger then we can imagine. IMHO. Less
ASK SITTING AT .203 NICELY HERE WE GO
it was hard and i stayed because it was very sketchy and i had a feeling this was a been planned with by bigger hands
the big boys wouldnt waste there time.
APDN TO THE MOON
I DOUBLED DOWN MY INVESTMENT AT .13 AND VERY GLAD I DID!!!!!!
bite my tongue bruce posted the pr
so we have a new managing director?
that cant be why we ran from .12 -.20
very very nice start to a BIG WEEK
are we still running without a pr?
because if we are that is huge
50k at .185 :( looks like i wont do enough damage with my 13 bucks after all....
honestly the little pull back is just the IMPATIENT swing traders attempting to jump in and out struck out again
we should gap right back up to .195 when the "day traders" step right back in monday
whatch me slap the ask end of day with my 13.90 left on etrade
im gonna slap for like 20 shares at 3.59
Never ind we just had a 125 k buy green at .195
15000 traded at .195 was the one trade above .194
Lets see if we close closer to .20 that the high for the day
We are on the same page
Very sketchy
I'm sure this is manipulation bid dropped from .192 ask .191 bid to .184 bid of 60k ask .195
Horse $hite
Swing traders will get hurt!
Leave in the dust.
Over 1 mil volume
BECAUSE IT WAS MANIPULATED DOWN IN THE FIRST PLACE PLEASE COMON MAN!!!!!!!!!!!!!!!!!!!!!!!
You are long and you really think apdn was priced right at .12 .13 !!!?!?!?!!!
3 days green and no real or or big news
Things that make u go hmmmmmmmmmmm....
6k vol is very sad 2 small trades totaling 6.46 k is a sad story
9k left at .185 getting thin
2 mil plus volume!
Markets down apdn is green w/ 1.25 mil volume
Close above .19????
Someone has a tight grip on apdn being controlled for sure